Movement Disorder News and Research

Latest Movement Disorder News and Research

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Pico-Tesla, The Magneceutical Company, announced that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa.

5 Jan 2011

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Manhattan Pharmaceuticals, Inc. announced preliminary results today from a Phase 1/2 study of AST-915 for the treatment of essential tremor. Data from this single dose study demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power.

16 Dec 2010

African American patients less likely to receive medications for parkinsonian symptoms

African American patients and those with lower socioeconomic status have more advanced disease and greater disability when they seek treatment from Parkinson's disease specialists, according to a study from the University of Maryland School of Medicine.

14 Dec 2010

Research programs embody the promise of anti-aging medicine.

Sometimes the value of research lies as much in exposing false remedies as in discovering true breakthroughs. Scientists at the country's first school of gerontology and in laboratories around the University of Southern California do both, mindful of their responsibility to a society focused on healthful aging.

13 Dec 2010

IETF announces March as National Essential Tremor Awareness Month

The International Essential Tremor Foundation is proud to announce that the United States House of Representatives formally passed House Resolution 1264 sponsored by Congressman Dennis Moore officially designating the month of March as "National Essential Tremor Awareness Month".

10 Dec 2010

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.

4 Dec 2010

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

Nearly three-quarters of patients with Parkinson's disease experience fatigue or excessive daytime sleepiness (EDS), but clinicians should assess both problems separately in order to improve the profession's understanding of their distinct, but overlapping, physiology. That is the key finding of a study published in the December issue of the European Journal of Neurology.

1 Dec 2010

FDA clears Multi-Lead Trialing Cable for SCS therapy

Medtronic Inc., the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA) clearance and the global launch of the Multi-Lead Trialing Cable for use in the patient screening test for Medtronic spinal cord stimulation (SCS) therapy.

19 Nov 2010

Specific brain changes suggest new therapeutic targets for Alzheimer's disease

New studies identify brain changes in people with Alzheimer's disease. The results give researchers a greater understanding of the disease and may help at-risk individuals by improving early detection. New animal research also shows a novel approach to Alzheimer's vaccine design that may avoid dangerous side effects. These new results were reported at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

17 Nov 2010

Integra launches CRW Precision Arc Stereotactic System for neurosurgery

Integra LifeSciences Holdings Corporation announced today the launch of the CRW Precision™ Arc Stereotactic System, a multi-purpose stereotactic system used for localizing intra-cranial targets and precisely directing instruments to the target in cases such as brain biopsy, tumor resection, and Deep Brain Stimulation (DBS) surgeries.

18 Oct 2010

Study suggests treating RLS may improve sleep and quality of life in people with fibromyalgia

A study in the Oct. 15, 2010 issue of the Journal of Clinical Sleep Medicine found that adults with fibromyalgia had a much higher prevalence and risk of restless legs syndrome than healthy controls. The study suggests that treating RLS may improve sleep and quality of life in people with fibromyalgia.

15 Oct 2010

Experts reach consensus about DBS treatment for Parkinson's disease

Since the late 1990s, deep brain stimulation (DBS) has proven to be a lifeline for some patients suffering from Parkinson's disease, a cruel neurological disorder that can cause lack of control over movement, poor balance and coordination, and rigidity, among other symptoms.

14 Oct 2010

UCB, Synosia Therapeutics announce new strategic partnership in neurology

UCB and Synosia Therapeutics announced today a new strategic partnership in neurology. Synosia has granted UCB a license for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications. Both are in Phase II clinical development for the treatment of Parkinson's disease.

12 Oct 2010

Microglial inflammation promotes MAPT pathologies

Cells that help to protect the central nervous system may also contribute to pathological changes in the brain. New research, published by Cell Press in the October 7th issue of the journal Neuron, provides mechanistic insight into a link between the immune system and neurodegenerative disorders like Alzheimer's disease that are associated with abnormal accumulation of tau protein.

7 Oct 2010

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

Penn Medicine selected as study site for PPMI

The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.

30 Sep 2010

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

The National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health, has established two new sites as part of the Morris K. Udall Centers of Excellence in Parkinson's Disease Research. The NINDS grants will provide a five-year investment totaling more than $16 million for Emory University in Atlanta and the Feinstein Institute for Medical Research in Manhasset, N.Y.

29 Sep 2010

Scientific update conference on Lyme and Tick-Borne Diseases

Lyme disease is a growing threat in the U.S., with numbers that continue to rise despite increased awareness about the disease. "Little is being done to stop the spread of Lyme disease and to help those who are suffering from chronic Lyme," says Pat Smith, president of the all-volunteer national Lyme Disease Association, which funds research, educates the public, and provides scientific conferences for doctors.

20 Sep 2010

Mayo Clinic opens newly expanded neurophysiology laboratory at Florida campus

Mayo Clinic unveiled a newly expanded, state-of-the-art neurophysiology laboratory on its Florida campus to provide additional services and care for more patients, many of whom are referred by community physicians for specialized diagnostic testing.

10 Sep 2010

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

TPP Global Development Ltd (TPP) announced an agreement with the University of Edinburgh to collaborate on the development of novel pre-clinical intellectual property originated within the University.

31 Aug 2010

Movement Disorder News and Research

Latest Movement Disorder News and Research

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

African American patients less likely to receive medications for parkinsonian symptoms

Research programs embody the promise of anti-aging medicine.

IETF announces March as National Essential Tremor Awareness Month

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

FDA clears Multi-Lead Trialing Cable for SCS therapy

Specific brain changes suggest new therapeutic targets for Alzheimer's disease

Integra launches CRW Precision Arc Stereotactic System for neurosurgery

Study suggests treating RLS may improve sleep and quality of life in people with fibromyalgia

Experts reach consensus about DBS treatment for Parkinson's disease

UCB, Synosia Therapeutics announce new strategic partnership in neurology

Microglial inflammation promotes MAPT pathologies

Neuraltus achieves last patient out for NP001, NP002 studies

Penn Medicine selected as study site for PPMI

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

Scientific update conference on Lyme and Tick-Borne Diseases

Mayo Clinic opens newly expanded neurophysiology laboratory at Florida campus

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Movement Disorder News and Research

Latest Movement Disorder News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in